Earlier this week, the Department of Health and Human Services (HHS) unveiled new regulations aimed at transforming how doctors and patients access prescription drug information in real time. The rule, set to take effect October 1, would require health care providers using certified health IT systems to instantly compare drug prices, review out-of-pocket costs, access prior authorization requirements, and electronically submit prior authorizations through an electronic health record. 

This regulation, crafted by the HHS Assistant Secretary for Technology Policy and the Office of the National Coordinator for Health Information Technology, builds on prior Centers for Medicare and Medicaid Services efforts to drive interoperability and slash administrative burdens. It’s part of a policy movement begun in June between HHS and insurers promising reforms to speed care and improve transparency. 

While technically regulatory in nature (somewhat in contradiction to the purported deregulatory unleashing of American innovation/wealth/power/etc.), this policy might actually accomplish the goal of real-time price comparisons and more rapid prior authorization determinations. At the heart of the initiative is a simple idea: When doctors and patients know what a medication will cost – and what alternatives are available – they can make smarter care decisions together. Suppose a patient is prescribed a particular drug at the doctor’s office. With a real-time prescription benefit tool, the physician can immediately see whether there’s a lower-cost, insurance-covered option that delivers the same clinical benefit. Instead of finding out at the pharmacy counter that the drug is unaffordable, the patient can walk away with a prescription they’re more likely to fill. 

Evidence suggests these tools can deliver meaningful benefits. Surescripts’ Real-Time Prescription Benefit tool, for example, has reported average savings of $82 per prescription and an 8.1-percentage point increase in fill rates when cheaper alternatives are surfaced. Electronic prior authorization is another major advantage, promising fewer delays, reduced paperwork, and ultimately more time for clinicians to focus on patient care. HHS estimates that millions of clinician hours – and billions of dollars in labor costs – could be saved across the system. 

Yet the relationship between transparency and price isn’t entirely straightforward. Large-scale studies, including one analyzing nearly 2.8 million Medicare Advantage patients, found no significant change in out-of-pocket or total prescription spending after these tools were introduced. RTPB tools have the potential to address physician behavior and patient adherence, but it is important to leverage the design of price transparency tools like RTPB to reduce barriers to accessing the information. The message is clear: Transparency doesn’t automatically translate into lower costs. There are challenges around implementation. A recent analysis of academic medical centers showed wide variability in how these systems were integrated into workflows. In some places, the tools helped streamline prescribing; in others, they were clunky, distracting, or underutilized. Much depends on thoughtful design, clinician training, and whether the tool enhances – or interrupts – the prescribing conversation. 

So, are real-time prescription benefit tools worth it? The answer lies somewhere between optimism and caution. On one hand, the potential is enormous: more informed decisions, higher adherence rates, less clinician burnout, and real cost savings for patients. On the other hand, the gains won’t come automatically. Without careful attention to usability, integration, and ongoing feedback from clinicians and patients, the tools could end up as yet another layer of health IT that promises more than it delivers. 

The HHS rule is best seen as a green light, not a guarantee. It gives health care organizations the framework and incentive to make these tools standard. But the true measure of success will depend on whether hospitals, practices, and technology vendors invest the time to embed them seamlessly, monitor outcomes, and adjust as they go. If they get it right, real-time prescription benefit tools could transform the act of prescribing into a smarter, more transparent process that benefits both patients and providers. If not, they risk becoming just another well-intentioned reform that falls short in practice.